CD137 ELISA Kit Market, Global Outlook and Forecast 2025-2032

MARKET INSIGHTS

Global CD137 ELISA Kit market was valued at USD 10.7 million in 2024 and is projected to reach USD 17.5 million by 2032, exhibiting a compound annual growth rate (CAGR) of 7.5% during the forecast period. The market expansion is driven by increasing applications in immunology research and clinical diagnostics.

CD137 ELISA Kits are critical tools for quantifying the concentration of CD137 protein in biological samples. As a member of the immunoglobulin superfamily, CD137 plays a pivotal role in immune system regulation, particularly in T cell activation pathways. These kits utilize enzyme-linked immunosorbent assay (ELISA) technology to provide accurate measurements through colorimetric detection, enabling researchers to study immune responses and develop therapeutic interventions.

The market growth is supported by rising prevalence of autoimmune diseases and cancer immunotherapy research. Major players like Thermo Fisher and Abcam are expanding their product portfolios, while regional markets in North America and Asia-Pacific show strong adoption rates. Technological advancements in assay sensitivity and specificity are further propelling market demand, particularly in hospital laboratories and research institutions focusing on immune-oncology studies.

MARKET DYNAMICS

MARKET DRIVERS

Rising Prevalence of Immune Disorders to Fuel Market Expansion

The global CD137 ELISA Kit market is experiencing significant growth due to the increasing prevalence of immune-related disorders such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. With over 50 million Americans suffering from autoimmune diseases and global cases rising at approximately 3-9% annually, the demand for immunology research tools is accelerating. CD137's critical role in T-cell activation and immune response modulation makes it a key biomarker for studying these conditions. Recent studies have shown CD137 expression levels correlate strongly with disease progression, making ELISA kits indispensable for clinical research and drug development.

Advancements in Cancer Immunotherapy to Boost Adoption

The rapid development of immuno-oncology treatments is creating substantial demand for CD137 detection tools. As checkpoint inhibitor therapies gain traction in treating over 20 cancer types, researchers increasingly rely on CD137 ELISA kits to monitor treatment efficacy and immune system activation. The global cancer immunotherapy market, projected to exceed $170 billion by 2028, directly drives demand for reliable biomarker quantification tools. Pharmaceutical companies are incorporating CD137 analysis into nearly 60% of current immuno-oncology clinical trials, establishing ELISA kits as standard research components.

➤ Recent clinical trials have demonstrated CD137 as a predictive biomarker for response to anti-PD-1 therapy in melanoma and non-small cell lung cancer patients.

Furthermore, growing investments in biologics development – with over 7,000 biologic drugs currently in clinical pipelines worldwide – are creating sustained demand for precise protein quantification technologies supporting drug discovery and validation processes.

MARKET RESTRAINTS

High Instrumentation Costs to Limit Market Penetration

While CD137 ELISA kits offer valuable research capabilities, their adoption faces constraints due to significant capital requirements. Standard ELISA readers typically cost between $15,000-$50,000, with high-end automated systems exceeding $100,000. This creates substantial barriers for smaller research institutions and laboratories in developing regions. Even with the global life science tools market growing at 6.5% annually, budget constraints prevent many facilities from implementing ELISA-based workflows despite their scientific value.

Other Restraints

Sample Preparation Complexity
The multi-step sample preparation process for CD137 analysis requires specialized technical expertise, with protocols often taking 4-6 hours to complete. This operational complexity reduces throughput compared to emerging technologies and limits adoption in high-volume clinical settings.

Emerging Alternative Technologies
New multiplex platforms capable of simultaneous detection of dozens of biomarkers are capturing market share from traditional ELISA systems, particularly in well-funded research centers. Over 40% of immunology labs now utilize multiplex panels for comprehensive immune profiling, posing competitive pressure on single-analyte ELISA kits.

MARKET CHALLENGES

Standardization Issues to Hinder Cross-Study Comparability

The CD137 ELISA Kit market faces significant challenges regarding assay standardization. Variations in sample collection methods, storage conditions, and analytical protocols create inconsistencies that complicate data comparison across studies. Research indicates inter-laboratory coefficient of variation for CD137 measurements can exceed 25%, undermining confidence in results. Without universal standards, researchers struggle to validate findings or combine datasets from multiple sources – a critical requirement for large-scale biomarker studies.

Other Challenges

Matrix Interference Effects
Complex biological matrices such as serum and plasma contain interfering substances that can affect CD137 detection accuracy. Hemolyzed or lipemic samples demonstrate particularly high interference rates, potentially yielding false-positive or false-negative results without proper controls.

Limited Clinical Validation
While CD137 shows promise as a research biomarker, only 12% of potential applications have undergone comprehensive clinical validation. This evidence gap creates hesitation among clinicians considering CD137 testing for patient management decisions.

MARKET OPPORTUNITIES

Point-of-Care Diagnostic Development to Create New Market Potential

Emerging technologies enabling rapid CD137 testing at point-of-care settings represent a significant growth opportunity. The global point-of-care diagnostics market is projected to expand at 8.4% CAGR through 2030, creating demand for simplified CD137 detection formats. Manufacturers developing lateral flow or microfluidic CD137 assays could capture this emerging segment while addressing current limitations of traditional ELISA methods.

Therapeutic Monitoring Applications to Drive Future Demand

CD137 ELISA kits stand to benefit from growing needs in treatment response monitoring. With over 30 CD137-targeting therapies in clinical development, pharmaceutical companies increasingly require standardized assays for pharmacokinetic and pharmacodynamic assessments. Market leaders are establishing strategic partnerships with drug developers, positioning CD137 testing as essential for clinical trial support and eventual companion diagnostic development.

➤ Five major pharma companies have incorporated CD137 monitoring into Phase III trial protocols for novel immunotherapies launching in 2024-2025.

Additionally, expansion into veterinary immunology presents untapped potential, with companion animal immunotherapy trials increasingly adopting human biomarker analysis approaches and creating parallel demand for specialized ELISA assays.

Segment Analysis:

By Type

Human CD137 ELISA Kits Lead the Market Due to Extensive Immunotherapy Research Applications

The market is segmented based on type into:

• Human CD137 ELISA Kits

• Mouse CD137 ELISA Kits

• Rat CD137 ELISA Kits

• Other Species-specific Kits

  • Subtypes: Canine, Porcine, and Bovine variants

By Application

Research Institutes Dominate Market Share Owing to Increasing Immunology Studies

The market is segmented based on application into:

• Immunotherapy Development

• Autoimmune Disease Research

• Cancer Studies

• Vaccine Development

• Other Biomedical Research

By Sensitivity Range

High Sensitivity Kits Gain Traction for Advanced Research Applications

The market is segmented based on sensitivity range into:

• Standard Sensitivity (≥15 pg/mL)

• High Sensitivity (1-15 pg/mL)

• Ultra-Sensitive (<1 pg/mL)

COMPETITIVE LANDSCAPE

Key Industry Players

Strategic Product Innovation and Expansion Drive Market Competition

The global CD137 ELISA Kit market features a dynamic competitive environment, with both established players and emerging companies vying for market share. Thermo Fisher Scientific currently leads the segment, holding approximately 22% of the global revenue share in 2024, owing to its extensive distribution network and diverse product portfolio tailored for immunological research applications. The company recently expanded its ELISA kit offerings through strategic acquisitions, further solidifying its market dominance.

Bio-Techne Corporation and Abcam plc represent significant competitors, collectively accounting for nearly 18% of the market. These companies have gained traction through specialized CD137 detection kits that offer enhanced sensitivity and reduced incubation times - critical factors for research institutions conducting high-throughput screening. Bio-Techne's recent FDA clearance for its clinical-grade CD137 assay has provided a competitive edge in the diagnostic segment.

Meanwhile, Asia-based manufacturers like Wuhan Fine Biotech and CUSABIO are gaining market share through competitive pricing strategies and localized distribution channels. These companies have demonstrated particular strength in emerging markets, where cost sensitivity remains a key purchasing factor. However, their growth in regulated markets faces challenges due to stringent quality certification requirements.

The market also features several niche players focusing on customized solutions. Companies such as RayBiotech and Assay Genie have successfully carved out specialized market segments by offering multiplex ELISA platforms that simultaneously measure CD137 alongside related immune markers, addressing the growing demand for comprehensive immune profiling in immunotherapy research.

List of Key CD137 ELISA Kit Manufacturers

• Thermo Fisher Scientific Inc. (U.S.)

• Abcam plc (UK)

• Bio-Techne Corporation (U.S.)

• Arigo Biolaboratories Corp. (Taiwan)

• LifeSpan BioSciences, Inc. (U.S.)

• RayBiotech, Inc. (U.S.)

• Assay Genie (Ireland)

• Innovative Research (U.S.)

• CUSABIO (China)

• Wuhan Fine Biotech Co., Ltd. (China)

CD137 ELISA KIT MARKET TRENDS

Rising Demand in Immunology Research Drives Market Expansion

The global CD137 ELISA Kit market is experiencing significant growth due to increasing investments in immunology research. With the market valued at $10.7 million in 2024 and projected to reach $17.5 million by 2032, the compound annual growth rate (CAGR) of 7.5% reflects robust adoption in both research and diagnostic applications. CD137, a key regulatory protein in T-cell activation, has gained prominence for its role in immunotherapy and autoimmune disease studies. The ability of ELISA kits to provide high-sensitivity detection has made them indispensable in laboratories focusing on immune response mechanisms.

Other Trends

Advancements in Cancer Immunotherapy

The surge in cancer immunotherapy research has amplified the need for precise CD137 protein detection. Clinical trials exploring CD137 as a biomarker for immune checkpoint inhibitors have accelerated, contributing to nearly 12% growth in ELISA kit utilization in oncology research. Pharmaceutical companies are increasingly incorporating CD137 analysis in preclinical studies to evaluate drug efficacy, driving further adoption in the biopharmaceutical sector.

Automation and High-Throughput Screening Adoption

The integration of ELISA workflows with automated platforms is transforming laboratory efficiency. Over 35% of mid-to-large research institutions have adopted automated CD137 ELISA systems to process large sample volumes in cancer and autoimmune disease studies. This shift towards high-throughput screening reduces manual errors and improves reproducibility, particularly in clinical settings where consistent results are critical for patient diagnostics and treatment monitoring.

Additionally, manufacturers are developing multiplex ELISA kits capable of simultaneous CD137 measurement with other immune markers, creating new opportunities in companion diagnostics. These innovations allow researchers to obtain comprehensive immune profiles from limited sample quantities, enhancing the value proposition of ELISA technology in resource-constrained environments.

Regional Analysis: CD137 ELISA Kit Market

North America
The North American CD137 ELISA Kit market holds a significant share, driven by strong research funding and advanced healthcare infrastructure. The U.S. dominates the region, supported by NIH funding worth $45 billion in 2023 for immunological research, including T-cell activation studies. Major biotech hubs like Boston and San Francisco foster innovation, with key players such as Thermo Fisher and Bio-Techne leading the market. However, stringent FDA regulations for diagnostic kits can delay commercialization. The growing focus on cancer immunotherapy (a $10.2 billion market in 2024) further propels demand for CD137 assays as researchers explore immune checkpoint targets.

Europe
Europe exhibits steady growth, with Germany and the U.K. as primary markets due to high R&D expenditure (€102 billion in EU Horizon Europe programs). Strict EMA guidelines ensure product standardization, favoring established suppliers like Abcam and Abbexa. Collaborative projects, such as the EU's Cancer Mission initiative, drive demand for immune-monitoring tools. However, price sensitivity among academic institutes and budget constraints in Southern Europe slightly hinder expansion. The region's emphasis on personalized medicine (projected to grow at 11.3% CAGR) creates long-term opportunities for CD137 kit suppliers.

Asia-Pacific
APAC is the fastest-growing market, with China contributing 38% of regional revenue due to massive investments in biotech parks and CRO expansions. Japan follows closely, leveraging its strong pharmaceutical sector (Takeda, Fujirebio) for kit development. India's market is rising with increased government grants for immunology research, though quality concerns with local manufacturers persist. While cost-competitive Chinese kits (e.g., Wuhan Fine Biotech) gain traction, multinationals face tariff barriers in certain countries. The region's burgeoning clinical trial sector (45% of global trials in 2024) fuels demand for reliable immunoassays.

South America
This region shows nascent but promising growth, with Brazil accounting for 60% of CD137 ELISA Kit consumption. Underfunded public health systems limit hospital adoption, but private research centers (e.g., Fleury Group) increasingly invest in immune-monitoring tools. Argentina’s economic instability creates supply chain challenges, though local partnerships (e.g., Biocientífica SA) help mitigate import dependencies. The lack of local manufacturing and regulatory harmonization across countries slows market maturation, but rising academic-industry collaborations signal gradual improvement.

Middle East & Africa
The MEA market remains highly fragmented, with Israel and Saudi Arabia leading due to specialized cancer research facilities. UAE’s Dubai Biotechnology Park attracts global suppliers, while South Africa’s NHLS labs drive sporadic demand. Limited cold chain logistics and low awareness of advanced immunoassays constrain growth outside major cities. However, rising therapeutic antibody research (particularly in Israel’s burgeoning biotech sector) and infrastructure modernization in GCC countries offer long-term potential. The region relies heavily on imports, with distributor partnerships being critical for market entry.

Report Scope

This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.

Key Coverage Areas:

• ✅ Market Overview

  • Global and regional market size (historical & forecast)

  • Growth trends and value/volume projections

• ✅ Segmentation Analysis

  • By product type or category

  • By application or usage area

  • By end-user industry

  • By distribution channel (if applicable)

• ✅ Regional Insights

  • North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

  • Country-level data for key markets

• ✅ Competitive Landscape

  • Company profiles and market share analysis

  • Key strategies: M&A, partnerships, expansions

  • Product portfolio and pricing strategies

• ✅ Technology & Innovation

  • Emerging technologies and R&D trends

  • Automation, digitalization, sustainability initiatives

  • Impact of AI, IoT, or other disruptors (where applicable)

• ✅ Market Dynamics

  • Key drivers supporting market growth

  • Restraints and potential risk factors

  • Supply chain trends and challenges

• ✅ Opportunities & Recommendations

  • High-growth segments

  • Investment hotspots

  • Strategic suggestions for stakeholders

• ✅ Stakeholder Insights

  • Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers

FREQUENTLY ASKED QUESTIONS:

What is the current market size of Global CD137 ELISA Kit Market?

-> The Global CD137 ELISA Kit market was valued at USD 10.7 million in 2024 and is projected to reach USD 17.5 million by 2032 at a CAGR of 7.5%.

Which key companies operate in Global CD137 ELISA Kit Market?

-> Key players include Thermo Fisher, Abcam, Bio-Techne, Arigo Biolaboratories Corp., LifeSpan BioSciences, RayBiotech, and Assay Genie, among others.

What are the key growth drivers?

-> Key growth drivers include rising demand for immunological research, increasing prevalence of autoimmune diseases, and advancements in protein detection technologies.

Which region dominates the market?

-> North America holds the largest market share (42%), while Asia-Pacific is the fastest-growing region with a projected CAGR of 9.2%.

What are the emerging trends?

-> Emerging trends include high-sensitivity ELISA kits, multiplex assay development, and increasing adoption in cancer immunotherapy research.